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Summary
Triptolide, a diterpene triepoxide isolated from the tra-
ditional Chinese medicinal vine Trypterygium wilfordii
hook f., has been shown to induce rapid apoptosis in
a myriad of cancer cell lines and inhibit NFkB transac-
tivation. To understand further the general cellular
mechanisms for this therapeutically relevant natural
product, binding and biological activities were as-
sessed. Studies showed that triptolide binding was
saturable, reversible, and primarily localized to cell
membranes. Depletion of calcium enhanced overall
binding while differentially modulating biological func-
tion. Furthermore, triptolide’s structural moieties dem-
onstrated variability in the regulation of cell death ver-
sus inhibition of NFkB transactivation. These results
implicate triptolide in the manipulation of at least two
distinct cellular pathways with differing requirements
for calcium and effective triptolide concentration in or-
der to elicit each particular biological function.
Introduction
Traditional Chinese herbal therapy has utilized the herb
lei gong teng for centuries to treat inflammatory disor-
ders such as rheumatoid arthritis [1, 2]. Triptolide, one
of the active anti-inflammatory small molecules present
in the plant extract, has been shown to possess multiple
biological activities, as it also exhibits antitumor, immu-
nosuppressive, and antifertility effects [3–8]. Although
the efficacy of triptolide as an inhibitor of immune func-
tion and an inducer of tumor cell death has been well-
documented, its modes of action have not been thor-
oughly characterized.
Multiple studies have shown that triptolide inhibits
TNF-a- and IL-1b-induced transcription at a step after
NFkB binding to DNA [9]. While upstream activation of
the IKK complex, phosphorylation of IkBa, and NFkB nu-
clear translocation are not disrupted upon triptolide ad-
dition, it is postulated that triptolide may interfere with
additional p65 modifications or the recruitment of a tran-
scriptional cofactor. Triptolideadditionally inhibitsNF-AT,
but at the level of its nuclear translocation, a process
normally regulated by calcineurin and calcium flux [9].
A third transcription factor adversely regulated by tripto-
lide is AP-1, whose nuclear translocation is blocked in re-
sponse to such stimuli as PMA and the calcium iono-
phore ionomycin [10, 11].
*Correspondence: craig.crews@yale.eduIn addition to its ability to attenuate the immune re-
sponse, triptolide also possesses potent antitumor effi-
cacy against leukemias, lymphomas, as well as solid tu-
mors [5, 12]. At different concentrations, triptolide either
arrests cell growth or actively induces cell death via
apoptosis [13]. Moreover, the therapeutic potential of
triptolide has been demonstrated by its synergistic ef-
fect with other anticancer agents [14–16], and it is cur-
rently in clinical trials for prostate cancer [13].
Structure-activity relationship studies indicate that
different pharmacophores are required for the various
biological effects of triptolide. While disruption of the
12,13 epoxide group or C-14 hydroxyl group of triptolide
has been reported to eliminate its anti-inflammatory
or immunosuppressive functions, respectively [17], the
9,11 epoxide was deemed necessary for its antitumor
effect [18]. These studies raise the question of whether
the various physiological effects of triptolide (i.e., anti-
inflammatory, proapoptotic) are elicited by a common
mechanism of action and/or interaction with a common
protein target.
In this study, we first assessed the properties of trip-
tolide binding activity in cells and discovered a link to
calcium dependence. We therefore examined the ef-
fects of calcium on two discrete endpoints of triptolide’s
action in the cervical carcinoma cell line HeLa: induction
of cell death and NFkB inhibition after TNF-a treatment.
Additionally, we tested the ability of triptolide analogs to
compete for binding and measured their capacity to af-
fect these biological endpoints. Our findings demon-
strate the following: (1) NFkB transcriptional inhibition,
while being a calcium-independent phenomenon, is
sensitive to disruption of the 12,13 epoxide and requires
a higher triptolide concentration than that sufficient to
induce cell death. (2) Triptolide-induced cell death is
strongly affected by calcium levels and is partially de-
pendent upon the functionality of the C-14 hydroxyl.
Results
[3H]Triptolide Binding Is Reversible and Associates
with Cell Membranes
To gain insight into triptolide’s mechanism of action, we
sought to determine its specific binding activity by uti-
lizing a system employing [3H]triptolide. In addition to
competition with 1 mM or 10 mM unlabeled triptolide,
we also measured the binding affinities of triptolide ana-
logs (Figure 1A). These analogs have been previously
described and differ structurally from triptolide in the
hydrolysis of the 12,13 epoxide (2) and in formation of the
ketone at the C-14 hydroxyl (3) (Figure 1A). HeLa cells
readily bound [3H]triptolide during an hour-long incuba-
tion, and binding was significantly competed with pre-
treatment of an excess of unlabeled triptolide (1–10 mM)
(Figure 1B). At either 1 or 10 mM, both triptolide analogs
showed near total displacement of [3H]triptolide (Fig-
ure 1B). The effective interaction of these analogs with
a presumed triptolide binding entity led us to their use
in subsequent experiments addressing the mode of trip-
tolide’s biological functions.
Chemistry & Biology
1260To address first the nature of triptolide binding within
the cell, we determined that this interaction was revers-
ible, as [3H]triptolide labeling was out competed by sub-
sequent addition of excess unlabeled triptolide (Fig-
ure 2A). An additional labeling experiment followed by
cellular fractionation indicated that [3H]triptolide binds
predominantly to the membrane fraction (P-100) of the
cell (Figure 2B). Although 25% of the total cellular counts
(i.e., representing bound triptolide) were found in the cy-
tosolic fraction, it is uncertain whether this is specific
binding or simply that free triptolide had dissociated
from its binding protein due to experimental manipula-
tion during fractionation. Since our data thus far had
only shown binding within whole cells, we next deter-
mined if this triptolide binding protein could be further
characterized and/or enriched by its association with
chromatographic reagents. HeLa cells were once again
labeled with [3H]triptolide, and total cell lysates were
then passed over the anion exchange resin DEAE. Batch
elutions with increasing NaCl concentrations were used
to disassociate interactions of variable charge. Substan-
tial elution of [3H]triptolide was not seen in the flow-
through or with several salt-free washes, and, in fact, it
Figure 1. Triptolide Analogs and Their Structural Dependence to
Compete for Binding
(A) Structures of triptolide and the analogs used in this study.
(B) HeLa cells were treated with [3H]triptolide for 1 hr in all samples
after the addition of 10 mM or 1 mM triptolide, one of its analogs, or
no competition also for 1 hr. Cells were washed, total cell lysates
were prepared, and samples were counted for bound [3H]triptolide
activity. CPM = counts per minute by scintillation counting. n = 3;
data represented as mean 6 SE.did not begin to elute until the addition of 0.2 M NaCl
(Figure 2C). Additionally, free [3H]triptolide diluted in ly-
sis buffer and then passed over this resin eluted in the
Figure 2. Triptolide Binding Is Specific, Membrane Localized, and
Saturable
(A) HeLa cells were treated with [3H]triptolide for 1 hr in all samples.
Competition of the radioligand was assessed by the addition of 1 mM
unlabeled triptolide (cold) for 1 hr either before or after [3H]triptolide
addition. CPM = counts per minute by scintillation counting. n = 3;
data represented as mean 6 SE.
(B) HeLa cells were labeled with [3H]triptolide, and cellular fractions
were prepared. Binding was assessed as total CPM in the cytosolic
(S-100), membrane (P-100), or insoluble cellular fractions.
(C) HeLa cells were labeled with [3H]triptolide for 1 hr, followed by
preparation of total cellular lysates and addition to DEAE anion ex-
change resin. The resin was washed in batch elutions of increasing
salt concentration after removal of the flow-through (FT). Each eluant
was subsequently counted for [3H]triptolide activity. n = 3; data rep-
resented as mean 6 SE.
(D) [3H]triptolide-labeled HeLa cell P-100 fractions were run out on
8% reducing or native PAGE. Gel slices were removed by utilizing
molecular weight marker designations, crushed, eluted in water,
and were then counted for [3H]triptolide activity by scintillation
counting. n = 2; data represented as mean 6 SD.
(E) HeLa cells were preincubated with 2 mM unlabeled triptolide or
DMSO, followed by increasing nanomolar concentrations of [3H]trip-
tolide for 1 hr. Specific binding was measured from scintillation
counting of cellular lysates, and receptor saturation was achieved.
Nonspecific binding (NSB) is shown in the inset and does not reach
saturation.
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that triptolide alone does not interact with this chro-
matographic media (data not shown). Importantly, we
also observed that [3H]triptolide would only bind to in-
tact cells in culture, but would not bind to any compo-
nent of a total cellular lysate, as assessed by interaction
with the DEAE resin (data not shown). Negative results
for a triptolide binding interaction were also observed
with DNA-cellulose and the cation exchange resin SPFF
(sulphopropyl) (data not shown).
Another line of evidence for direct protein interaction
involved an additional separation of [3H]triptolide-
labeled membrane preparations. Labeling of cells and to-
tal membrane purification by high-speed centrifugation,
followed by detergent resolubilization, yielded samples
that were run out on 6% polyacrylamide gels under na-
tive or denaturing conditions (the [3H]triptolide lysates
were not boiled in either experimental condition). Gel
slices were extracted based on molecular weight range
and crushed, and water was extracted, followed by
liquid scintillation. Native gel separation indicated that
[3H]triptolide was bound to protein(s) above 250 kDa,
while denaturing conditions showed a separation of
[3H]triptolide binding in a range from 75 to greater than
250 kDa (Figure 2D). These results suggested that tripto-
lide could be binding to a protein complex that then dis-
sociates upon reducing conditions. These data are also
supported by size-exclusion assays from total cell ly-
sates, in which the majority of [3H]triptolide binding
activity was recovered above a molecular weight of
100 kDa (data not shown).
Based upon our data described above, we next
sought to determine if triptolide binding was saturable
and if more than one protein (or binding site) was being
targeted. Determination of the [3H]triptolide binding af-
finity (KD) and the binding capacity per cell (Bmax)
were calculated by using a saturation plot. HeLa cells
were cultured to 90% confluency and were subse-
quently treated with 0–100 nM [3H]triptolide for 1 hr.
Nonspecific binding was defined by using 2 mM cold
triptolide as competitor. Bmax was calculated to be
996 19 fmol triptolide bound/105 cells of triptolide bind-
ing sites. Specific binding was found to be saturable,
with a KD value of 15.56 0.8 nM, while nonspecific bind-
ing was linear (nonsaturable) (Figure 2E).
Triptolide Binding Activity Is Influenced
by Extracellular Calcium Concentration
To understand further the nature of triptolide’s interac-
tion within the cell, we altered cell culture conditions to
examine if [3H]triptolide binding would be affected. Cal-
cium has been shown to mediate numerous cellular
functions, including transcriptional activation of NF-AT
and NFkB [19–21]. Additionally, it has been established
that aberrant calcium signaling can result in cell death
[22, 23]. Due to triptolide’s own link with NFkB and
NF-AT and its propensity to induce cell death, we exam-
ined if triptolide binding could be modulated by free cal-
cium levels. Adherent HeLa cells were cultured in the pre-
sence or absence of calcium-containing medium for 16 hr
before [3H]triptolide addition. Replicate experiments
confirmed that, in the absence of extracellular calcium,
[3H]triptolide binding significantly increased between
2- and 4-fold, depending on cell number and density(Figure 3A). It is also noteworthy that an increase in
cell density (not cell number) also increases triptolide
binding regardless of calcium levels (data not shown).
Additionally, specific calcium chelation by 10 mM EGTA
for 1 hr in calcium-containing medium increased binding
by nearly 2-fold (data not shown). These data indicate
that the interaction of triptolide with its target protein(s)
is potentially stabilized or enhanced when calcium levels
are low.
Triptolide-Induced Cell Death Is Delayed
in the Absence of Calcium
Since extracellular calcium concentration can influence
triptolide binding, we sought to determine if the presence
of calcium influences the rate of triptolide-mediated apo-
ptosis. To first establish the growth rate of HeLa in me-
dia 6 calcium, cell counts were performed over a 72 hr
time course. Although calcium-free media caused cells to
detachmoreeasily, theoverall growthrates were similar—
cell doubling occurred every 24 hr on average (Figure 3B).
For triptolide experiments, cells were initially equilibrated
in medium 6 calcium for 16 hr before the addition of
100 nM triptolide. Cell death was assessed by trypan blue
dye exclusion at 24, 48, and 72 hr after drug treatment.
In the presence of calcium-containing medium, triptolide
Figure 3. Extracellular Calcium Regulates Triptolide-Mediated
Binding and Cell Death Induction
(A) HeLa cells were cultured in the presence or absence of calcium-
containing media for 16 hr before the addition of 30 nM [3H]triptolide
to assess binding affinity. CPM = counts per minute. n = 3; data rep-
resented as mean 6 SE.
(B) HeLa cells were cultured in the presence (+Ca2+) or absence
(2Ca2+) of calcium-containing media over a time course of 72 hr to
determine the rate of growth in each condition. n = 3; data repre-
sented as mean 6 SE.
(C) HeLa cells were cultured in the presence (+Ca2+) or absence
(2Ca2+) of calcium-containing media plus 100 nM triptolide over
a time course of 72 hr. Cells were washed with PBS, photographed,
and counted by using trypan blue at 0, 24, 48, and 72 hr to assess
viability. Results are representative of three separate experiments.
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continued through later time points (Figure 3C). In con-
trast, removal of calcium from the growth medium re-
sulted ina higherproportionof viablecells (Figure3C). Fol-
lowing 72 hr of triptolide addition in calcium-free media,
only35%ofthecellshaddied, indicatingthat there isasig-
nificant delay in this process. These results support a role
for calcium in efficient cell death induced by triptolide.
There is, however, a likely secondary (albeit slower) mech-
anism to promote apoptosis, as the lack ofcalcium merely
delays, but does not eliminate, cell death.
To investigate further the role of calcium in triptolide
function, we utilized a system to buffer intracellular cal-
cium levels. Various GFP-parvalbumin (PV) fusion pro-
teins can be specifically localized to either the nucleus
or the cytoplasm through a nuclear localization or exclu-
sion signal (NLS or NES, respectively) [24]. Parvalbumin
has two EF-hand calcium binding domains and can effi-
ciently reduce the availability of free calcium in the cell
[25]. HeLa cells were transiently transfected with the
GFP vector control, NES-PV-GFP, or NLS-PV-GFP in
calcium-containing media, and efficient expression of
each construct was determined by GFP localization (Fig-
ure 4A). Normal cell growth was first assessed through-
out 48 hr with each of the constructs. All transfections
resulted in normal growth doubling during the course
of the experiment without drug addition (Figure 4B).
For triptolide experiments, cells were transfected and
allowed to express the construct for 24 hr before the ad-
dition of 100 nM triptolide. After 24 and 48 hr of treat-
ment, cells were assessed for viability. Both control
GFP vector and NLS-PV-GFP showed similar apoptosis
induction, whereby 50% of the cells were rounded and
no longer viable after 24 hr (Figure 4C). In marked con-
trast, cytosolic parvalbumin (NES-PV-GFP) significantly
inhibited triptolide-induced cell death at this time point
(15%–20% apoptosis) (Figure 4C). This effect was tran-
sient, however, as there was complete cell death in all
conditions by 48 hr (data not shown). Since the parval-
bumin buffering experiments are done in the presence
of extracellular calcium, the cell can operate normally,
in that intracellular calcium stores may be refilled. It is
reasonable to expect, then, that if calcium homeostasis
is being affected (i.e., cytosolic calcium levels increase)
by triptolide, then parvalbumin would eventually reach
a saturation point. This might explain why the rescue
from apoptosis is transient through the 24 hr time point
but is lost by 48 hr. These results not only confirm the
overall importance of calcium to triptolide function, but
they more specifically point to cytosolic calcium levels
as mediators in triptolide-induced cell death.
Inhibition of NFkB Transactivation by Triptolide
Is Calcium-Independent
Having established that triptolide induced cell death is
dependent upon free calcium concentration, we next
determined if this was also a requirement for the inhibi-
tion of NFkB transcription. HeLa cells were transiently
transfected with the kB-luciferase reporter construct
for 8 hr before being washed and then cultured in the
presence or absence of calcium-containing medium
for 16 hr. Triptolide (100 nM) was preincubated with cells
for 1 hr before the addition of 15 ng/ml TNF-a for 5 hr.
Similar profiles were seen in both the presence and ab-sence of calcium as TNF-a induced NFkB transactiva-
tion, while triptolide effectively inhibited it (Figure 5A).
As an additional experiment, transcriptional activity
was also assessed by site-directed calcium buffering.
HeLa cells were cotransfected with the kB-luciferase
plasmid as well as one of the following constructs: GFP
empty vector, NES-PV-GFP, or NLS-PV-GFP. Proper
GFP localization was confirmed. Cells were grown in
the presence of calcium for 24 hr before the addition
of 100 nM triptolide and 15 ng/ml TNF-a. NFkB transac-
tivation by TNF-a alone was quite high, although both
NES- and NLS-parvalbumin-transfected cells showed
slightly lower levels of luciferase expression as com-
pared to the vector control. Importantly, triptolide still
retained the ability to suppress NFkB transactivation in
all experimental conditions (Figure 5B). These results
suggest that, while efficient induction of apoptosis by
triptolide is calcium-dependent, inhibition of NFkB tran-
scriptional control is not.
Triptolide Concentration Differentially Affects
Cell Death and Inhibition of NFkB
Our results have implicated reversible binding of tripto-
lide to a potential binding protein or complex that can be
regulated by calcium. To understand if triptolide func-
tion is further separable between cell death and NFkB in-
hibition, we examined the effect of concentration on
Figure 4. Buffering Cytosolic Calcium Can Temporarily Rescue
Triptolide-Induced Cell Death
(A) HeLa cells were cultured in the presence of calcium-containing
media and were transfected with one of the following constructs for
24 hr: GFP vector, NLS-parvalbumin (PV)-GFP, NES-PV-GFP. Im-
ages were acquired by confocal microscopy (403).
(B) Normal cell growth was assessed with each transient transfec-
tion construct. n = 3; data represented as mean 6 SE.
(C) 100 nM triptolide was added to all transfected cells, and viability
was assessed after 24 hr. n = 3; data represented as mean 6 SE.
Calcium Dependence of Triptolide Function
1263these two endpoints. HeLa cells were cultured in the
presence of 0, 10, 25, 50, or 100 nM triptolide and were
separately assessed for cell death or the ability to sup-
press NFkB transactivation promoted by TNF-a. Follow-
ing 24–48 hr of culture, viable cells were recovered and
counted. Following 24 hr, triptolide concentrations from
25 to 100 nM caused greater than 50% of the cells to un-
dergo cell death, as assessed by detachment, clumping,
and the failure to exclude trypan blue dye (data not
shown). After 48 hr, nearly all cells treated within this
concentration range of triptolide died (Figure 6A). While
untreated HeLa cells underwent two cycles of division,
10 nM triptolide inhibited cell proliferation, but did not in-
duce cell death. This is consistent with previous studies
showing that low doses of triptolide cause cell cycle ar-
rest rather than apoptosis [13]. It is also of note that trip-
tolide’s action on the cell, which ultimately results in cell
death, is initially reversible, as 3–4 hr is the minimal incu-
bation time required for commitment to apoptosis (data
not shown).
NFkB transactivation was examined by using the kB-
luciferase reporter construct. HeLa cells were tran-
siently transfected and pretreated with 0–100 nM tripto-
lide for 1 hr prior to TNF-a addition. Cells were assessed
for NFkB-driven luciferase expression after an addi-
tional 5 hr of incubation, at which time TNF-a had in-
Figure 5. Inhibition of NFkB Transactivation Is Independent of the
Presence of Calcium
(A) HeLa cells were transfected with a kB-luciferase construct for all
experimental conditions for 24 hr before the addition of 15 ng/ml
TNF-a 6 100 nM triptolide. Cells were grown in the presence or ab-
sence of calcium-containing media for 16 hr before treatment and
were then harvested for the assay after 6 hr. n = 4; data represented
as mean 6 SE.
(B) At the same time as the kB-luciferase construct, cells were trans-
fected with one of the following: GFP vector, NES-PV-GFP, NLS-
PV-GFP. They were the treated as described in (A). n = 4; data repre-
sented as mean 6 SE.duced transcriptional activity by approximately 15-fold
in control cells. Neither 10 nM nor 25 nM triptolide in-
hibited TNF-a-driven transcriptional activity of NFkB
(these concentrations are shown to inhibit proliferation
or induce cell death, respectively), whereas 50 nM tripto-
lide suppressed activity by 20%. The concentration of
100 nM had the most profound effect, exhibiting an av-
erage of 60% inhibition (Figure 6B). It is also of note
that luciferase activity assayed after 24 hr with 10 nM
triptolide + TNF-a still showed greater than a 20-fold in-
duction (data not shown). Examination of these two bio-
logical endpoints at the same chronological time indi-
cates that, while 10 nM is efficient at arresting cell
growth, it cannot inhibit TNF-a-induced NFkB transcrip-
tional activity. The results thus far support a divergence
of triptolide-mediated functions: the pathway regulating
growth arrest/death is more sensitive to triptolide and
calcium than the mechanism leading to transcriptional
repression of NFkB.
Triptolide Analogs Show Differential Abilities to
Induce Cell Death or Inhibit NFkB Transactivation
Based on our studies examining the concentration-
dependent effect of triptolide on the two measured
Figure 6. Triptolide Concentration Differentially Affects Viability/
Growth or NFkB Inhibition
(A) HeLa cells were plated at an initial concentration of 5 3 105 and
were allowed to grow 6 triptolide (10–100 nM) for 48 hr. Viable (ad-
herent) cells were photographed under 253 bright-field micros-
copy, and cell death was assessed by trypan dye exclusion. Re-
sults are representative of three separate experiments.
(B) After a transient transfection with the kB-luciferase reporter
construct, HeLa cells were incubated with 15 ng/ml TNF-a 6 tripto-
lide (10–100 nM) for a total of 6 hr before assessing reporter activ-
ity. n = 4; data represented as mean 6 SE.
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(A–C) All experiments were done with HeLa cells, and cell viability was measured 24 hr after the addition of triptolide or one of its analogs at
concentration ranges of 0.1–10 mM. Cell viability was assessed by trypan dye exclusion and was recorded as the percent change in cell num-
ber from the time of triptolide or analog addition. Control cells were allowed to grow in media alone and represent a normal population dou-
bling; n = 3. NFkB Inhibition was assessed after transfection with the kB-luciferase reporter construct and treatment with triptolide or one of
its analogs (0.1–10 mM) and TNF-a for 5 hr. Control represents transfected cells without TNF-a addition. n = 4; data represented as mean 6 SE.
(A) Triptolide (1). (B) Triol-Triptolide (2). (C) Triptonide (3).biological endpoints, cell death and transcriptional re-
pression, we wanted to determine how modulating trip-
tolide’s structure may also discriminate between the two
pathways. For cell viability assays, HeLa cells were incu-
bated with 0, 0.1, 1, or 10 mM of each analog or triptolide
for 24 hr and then counted by using trypan blue dye ex-
clusion. Triptolide, as shown before, effectively induced
greater than 50% cell death at 0.1 mM, and there was no
significant increase at the higher concentrations (Fig-
ure 7A). NFkB transcriptional inhibition was measured
by using the kB-luciferase assay as previously described,
after 5 hr of incubation with each analog (0–10 mM) and
TNF-a addition. NFkB inhibition was greater than 60%
and attenuated further as triptolide’s concentration in-
creased to 1 or 10 mM (Figure 7A).
Upon disruption of the 12,13 epoxide in analog (2), dif-
ferential effects were seen in regard to each biological
endpoint. At 0.1 mM analog (2), cell viability was not dif-ferent from the untreated control (Figure 7B), as com-
pared to the w60% cell death observed at the equiva-
lent concentration of triptolide.
If cells were allowed to continually grow at 0.1 mM
analog (2) out to 72 hr, it became evident that there was
an overall growth-suppressive effect (data not shown).
Interestingly, 1 mM analog (2), a concentration that effi-
ciently competes with triptolide for binding (Figure 1B),
induced greater than 50% cell death, while having no
effect on NFkB transcriptional activity (Figure 7B). It
therefore appears that the mechanism of NFkB inhibi-
tion is more sensitive to the structural integrity of the
12,13 epoxide than is the cell growth/death regulatory
pathway.
The most potent and biologically similar analog to
triptolide was analog (3). Displacement of [3H]triptolide
binding was near complete at both the 1 and 10 mM con-
centrations (Figure 1B). In fact, 1 mM analog (3) actually
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at the same concentration (Figure 1B). Both profiles of
cell death and transcriptional repression mimicked trip-
tolide, and there was no significant difference from 0.1 to
10 mM (Figure 7C). It is of note, however, that at 25 nM,
a concentration shown to induce cell death by triptolide
(Figure 6A), analog (3) had only a growth-suppressive ef-
fect (data not shown). Since competition for binding by
analog (3) was so strong, these data would support the
idea that triptolide-induced apoptosis at its lowest
(25 nM) concentration is partially due to the functionality
of the C-14 hydroxyl.
Discussion
Triptolide is a natural product isolated from the ‘‘Thun-
der God Vine’’ that has a long-standing history of medic-
inal value. Of the many small molecules (i.e., glycosides,
terpenoids, and alkaloids) isolated from this herbal ex-
tract, triptolide has been shown to be one of the most bi-
ologically active. Its therapeutic value is high, as it has
been demonstrated to inhibit inflammation (i.e., rheuma-
toid arthritis), reduce T cell reactivity leading to immuno-
suppression (i.e., lupus erythematosus or organ trans-
plant rejection), induce apoptosis of cancerous cells,
and even act as a male contraceptive. Although tripto-
lide’s predominant cytotoxic effect is largely apparent
in lymphocytes and leukocytes, it is capable of inducing
cell death in numerous solid tumors, including prostate
[13], lung [26], breast, gastric carcinoma, and melanoma
[12].
While triptolide has numerous physiological func-
tions, there is minimal understanding of its precise
mode of action. Since triptolide is a highly oxygenated
diterpenoid with epoxides at the 7,8; 9,11; and 12,13 po-
sitions, it is plausible to believe that one or more is re-
sponsible for biological activity. In fact, previous research
has demonstrated that the 9,11 epoxide in conjunction
with the 14b hydroxyl may be responsible for triptolide’s
antineoplastic activity [18]. In contrast, the 12,13 epox-
ide has been implicated in both the anti-inflammatory
and immunosuppressive effects [17]. Therefore, this lim-
ited structure-activity relationship alone would indicate
that multiple cellular pathways are affected, and that
triptolide could potentially interact with more than one
target protein.
In this study, we sought to determine the general
specificity of triptolide binding and further focused on
two known endpoints of triptolide function: induction
of cell death and inhibition of NFkB transactivation. To
begin mechanism of action studies, we utilized [3H]trip-
tolide as a cellular probe and discovered that binding
was reversible and localized predominantly to the mem-
brane fraction of the cell. Evidence for protein associa-
tion was 2-fold: (1) a [3H]triptolide bound entity from
the anion exchange resin DEAE specifically eluted
upon an increasing step gradient of NaCl concentration,
where free [3H]triptolide eluted in the flow-through. (2)
Upon molecular weight fractionation by SDS-PAGE or
size-exclusion chromatography, bound [3H]triptolide
was associated with a high molecular mass (>250 kDa)
that dissociated under denaturing conditions. Total cel-
lular [3H]triptolide binding was found to be saturable,
with a KD of 15.5 nM, as shown by radioligand saturationplots. However, due to limitations with volume, we could
not test triptolide concentrations above 100 nM or with
precision below 5 nM; due to these constraints, we can-
not exclude the possibility of lower- or higher-affinity in-
teractions that may fall beyond the testable range.
Based on these data, it would be plausible that one
target of triptolide binding may be a large membrane-
associated protein or complex that at best supports
a model of a reversibly covalent or unstable interaction.
Additionally, since we discovered that the S-100 cyto-
solic fraction contained [3H]triptolide, we acknowledge
that this may be the result of specific binding to other
protein(s) or, conversely, may simply represent unbound
triptolide.
Further exploration into the nature of triptolide binding
led to the discovery of a calcium-dependent phenome-
non: calcium depletion significantly increased triptolide
binding while attenuating its proapoptotic function.
Specifically, since cytosolic calcium levels are responsi-
ble for efficient triptolide-induced cell death, it would be
of interest to determine if triptolide interacts with pro-
teins sensitive to calcium flux. One hypothesis is that
triptolide relies on a renewable source of calcium (such
as through the endoplasmic reticulum) to initiate apo-
ptosis by the disregulation of calcium homeostasis. In
fact, as previously reported [11, 27], triptolide induces
caspase activation, which could be the result of intracel-
lular calcium overload and subsequent mitochondrial
disruption.
Although calcium plays a role in triptolide-mediated
apoptosis, we found that it does not influence the inhibi-
tion of NFkB transactivation, as elimination of either ex-
tracellular calcium or cell compartment-directed parval-
bumin buffering had no effect. Since this divergence of
a calcium requirement exists for triptolide-mediated cel-
lular effects, it is reasonable to expect that more than
one intracellular pathway is involved. However, we can-
not know for certain if there is direct interaction with one
versus multiple binding proteins. Triptolide may bind to
a complex of proteins, thereby having the ability to ma-
nipulate multiple pathways while only interacting with
one multiplex target. Alternatively, there may be multiple
binding proteins with slightly higher or lower affinities
that would explain the closely titrated biological effects
of growth inhibition, cell death, and transcriptional sup-
pression seen within a 40 nM span of effective concen-
tration (10 nM, 25 nM, and 50 nM, respectively). Our re-
ceptor saturation data would support either case: (1)
one protein target or complex or (2) several protein tar-
gets with similar KD values, making it difficult to pharma-
cologically resolve these entities.
Our limited structure-function analysis of triptolide
binding and function involved the roles of the 12,13 ep-
oxide and the 14b hydroxyl of triptolide. Previous work
[17, 28] has demonstrated a link between the 12,13 ep-
oxide and triptolide’s anti-inflammatory activities by in
vivo models, while we have examined the direct effect
on NFkB transcription as well as binding properties of
this triptolide analog (2). While 1–10 mM competition
with analog (2) was just as efficient as triptolide, it was
only able to suppress transcriptional activity at the high-
est concentration of 10 mM, thereby supporting its im-
portance to triptolide’s anti-inflammatory activity. The
12,13 epoxide was not as crucial to triptolide’s role in
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an effect in this regard: 100 nM was growth inhibitory,
and 1–10 mM increased cell death to levels comparable
with triptolide. Triptonide analog (3) has been indepen-
dently shown to have potent anti-inflammatory, antineo-
plastic, and anti-male-fertility effects [29, 30], as well as
being a reversible degradation product of triptolide itself
[31]. Here, we have further established that analog (3) is
capable of competing with triptolide for its binding sites
and shares the efficiency of biological activity from 0.1 to
10 mM concentrations. However, a divergence in func-
tion was elucidated at 25 nM, the concentration at which
triptolide can cause complete cell death, but analog (3)
is slightly weaker, as it will only arrest the growth of cells.
Therefore, triptolide’s antineoplastic (pro-cell death) ac-
tivity can be only modestly reduced by the formation of
a ketone at C-14. These data lend further support to a di-
vergence of triptolide function through more than one
cellular pathway. In these pathways, the following are
the variables regulating biological activity: (1) structural
moieties of triptolide, (2) the biological concentration,
and (3) the dependence upon the presence of calcium.
Although triptolide may be acting on more than one
cellular process to elicit its physiological responses,
one intriguing finding is that depletion of calcium can
increase or stabilize triptolide binding while simulta-
neously weakening its apoptotic effect. This could be
explained by a conformational change of a protein sen-
sitive to free calcium concentrations (thereby facilitating
binding) while at the same time being unable to elicit
a functional response because that is also dependent
upon calcium (cell death is delayed). One family of
proteins that would meet these criteria would be the
broad category of calcium channels. In members of
this family, open channel conformation can be influ-
enced by calcium concentration, and the functional ef-
fect (i.e., calcium release), again, is dependent on a re-
newable supply of calcium. Other possibilities may be
the family of calcium pumps or sensors, as they too
are sensitive to calcium flux. In contrast, we also ob-
serve that triptolide’s inhibition of NFkB transactivation
is not regulated by calcium. It is possible that triptolide
blocks the recruitment of an essential transcriptional co-
factor to the NFkB complex or inhibits further modifica-
tion to NFkB directly (such as a phosphorylation event).
These two pathways, however (calcium-dependent
and -independent), probably converge to amplify the
apoptotic response, as seen with the synergistic effect
of triptolide plus TNF-a to promote apoptosis [15]. In
this regard, triptolide would trigger TNF-a-induced apo-
ptosis by inhibiting its proinflammatory transcriptional
activity, while having yet another (calcium-dependent)
mechanism to induce cell death as well. Removal of cal-
cium would therefore only slow down cell death, as tran-
scriptional repression, although slower, would ultimately
result in the same fate.
Resolving triptolide’s mode of action as well as poten-
tial binding proteins has proven to be complicated and
a challenging endeavor. From the earliest studies eluci-
dating the numerous cellular and physiological effects of
triptolide, it was clear that this natural product had a
broad spectrum of activity. The challenge lies with the
intricate separation of the mechanisms that are required
to inhibit inflammation, elicit immunosuppression, pro-mote tumor cell death, and even abrogate male fertility.
Future studies will require the biochemical identification
of potential triptolide binding proteins as well as estab-
lishment of the biological relevance of each.
Significance
Triptolide has a broad range of therapeutic potentials
ranging from attenuation of inflammation, suppres-
sion of autoimmunity, and the elimination or regres-
sion of certain tumors. Basic studies of triptolide’s
mechanisms of action are incomplete, and there is lit-
tle understanding of how this small molecule can elicit
such a broad range of effects. Utilizing [3H]triptolide as
a probe, we have examined the properties of triptolide
binding in the cell as well as addressed questions per-
taining to two well-described biological endpoints of
triptolide function: cell death and transcriptional re-
pression of NFkB. A specific triptolide binding activity
is present within intact cells, is reversible, associates
predominantly with cellular membranes, and is sen-
sitive to calcium levels. While triptolide binding in-
creases upon extracellular calcium depletion, it is se-
verely impaired in its ability to induce cell death. This
observed calcium dependence is specific to the regu-
lation of apoptosis, as triptolide’s effect on NFkB
transactivation is unaltered in the presence or ab-
sence of calcium. An overall separation of biological
effects can be further discerned when triptolide is pres-
ent at low nanomolar concentrations. While 10 nM is
growth inhibitory and 25 nM induces cell death, neither
of these concentrations can elicit transcriptional re-
pression. Limited structure-function analysis utilizing
triptolide analogs has demonstrated that, while com-
petitive binding for triptolide interaction sites is intact,
biological effects are highly dependent upon struc-
tural moieties. These findings implicate triptolide as
functioning through at least two separate pathways
distinguishable by calcium requirements, sensitivity
to drug concentration, and preference toward struc-
tural entities. Further, we have started to characterize
a specific triptolide interaction within the cell so that
triptolide binding proteins may be identified in the
future.
Experimental Procedures
Reagents
Triptolide was obtained from Sinobest, Inc. (China), and purity was
99%, as determined by HPLC. DMSO was used to dissolve triptolide
and was then directly added into culture media for all experiments.
Triptolide was tritiated by Sib Tech, Inc. (Newington, CT) and was re-
suspended in ethanol to a specific activity of 4–6 Ci/mmol. Purity
was >95%, as confirmed by RP-HPLC on a Hypersil C18 column
and by TLC on both C18 and silica gel. Epi-Triptolide/Triol-Triptolide
(C.A.S. No 147852-78-6) and Triptonide (C.A.S. No 38647-11-9) were
purchased from Sequoia Research Products (United Kingdom).
Cell Culture and Viability Studies
HeLa cells were incubated in DMEM or SMEM (Gibco) media + 10%
FBS and were maintained at 37ºC in 5% CO2 for all experiments.
HeLa cell viability was assessed by trypan blue dye exclusion, as
well as by morphological examination (nonviable cells were rounded
and detached from culture plate).
Calcium Dependence of Triptolide Function
1267[3H]Triptolide Labeling of HeLa Cells
Labeling studies were performed by the addition of approximately
30 nM [3H]triptolide directly into the culture media for 1 hr at 37ºC.
For cold competition studies, 1 mM triptolide was incubated with
the cells for 1 hr before or after the addition of [3H]triptolide. Tripto-
lide analog studies followed a similar protocol in which concentra-
tions used for competition were either 1 or 10 mM and were added
before [3H]triptolide. Medium was removed, and cells were washed
3 times in cold PBS. Total cell lysates were prepared (150 mM NaCl,
50 mM Tris-HCl [pH 7.4], 1 mM EDTA, 1% Triton X-100, and com-
plete protease inhibitors [Roche]), and protein was quantitated be-
fore measuring the [3H]triptolide binding activity via liquid scintilla-
tion.
DE-52 anion exchange resin (Whatman, Inc.), a diethylaminoethyl
(DEAE)-cellulose, was prepared for binding by a 1 M sodium chloride
(NaCl) wash, followed by multiple washes with 0 M salt buffer (10 mM
HEPES [pH 7.4], 0.1 mM EDTA, 1 mM DTT, 0.1% Triton X-100). HeLa
cell lysates labeled with [3H]triptolide were passed over the resin
and allowed to bind at 4ºC for 30 min before collecting the flow-
through and subsequent washes. A step gradient from 0.0 to
1.0 M NaCl was used for protein elution. All fractions were subse-
quently counted by liquid scintillation.
For cellular fractionation studies, cells were allowed to swell on ice
and were lysed by passage through a syringe in a hypotonic lysis
buffer (10 mM Tris-HCl + complete protease inhibitors). The lysate
was centrifuged at 100,000 3 g, and the supernatant was saved as
the S-100 cytosolic fraction. The pellet was washed and resolubi-
lized in 1% Triton X-100 containing lysis buffer. After centrifugation,
the supernatant was saved as the P-100 membrane fraction. Addi-
tionally, P-100 lysates were run out under native or reducing gel con-
ditions without boiling. Gel slices were measured out in equal incre-
ments, and the molecular weight range of each was calculated. Each
gel piece was crushed in ddH2O, followed by scintillation counting of
the water extract.
[3H]Triptolide-Specific Binding
Saturation binding assays were accomplished in HeLa cells adhered
on 6-well plates in DMEM + 10% FBS. All samples were at least 90%
confluent at the time of addition of triptolide. Nonspecific binding of
[3H]triptolide was assessed by the preincubation of 2 mM (nonla-
beled) triptolide for 1 hr. After cold competition (or DMSO), 5, 10,
20, 50, or 100 nM [3H]triptolide was added into the cultures for an
additional 1 hr, and then cells were lysed and counted for binding
activity.
Transfection of Parvalbumin Constructs
All parvalbumin-GFP constructs and control vectors [24] were a gift
of Anton Bennett (Yale University). HeLa cells were plated out on
6- or 12-well plates at a density of 5 3 105 or 1 3 105, respectively.
Cells were transiently transfected with 0.5–1 mg of one of the follow-
ing pcDNA3-derived plasmids for 24 hr in DMEM/10% FBS + Lipo-
fectamine 2000 (Invitrogen): CMV-parvalbumin-GFP, CMV-NES-
parvalbumin-GFP, CMV-NLS-parvalbumin-GFP. After confirmation
of GFP expression and localization by microscopy, 100 nM triptolide
was added into each transfected cell population (>90% transfection
efficiency). Cell viability was assessed at 24 and 48 hr after triptolide
addition by morphology and trypan blue dye exclusion.
NFkB Luciferase Assay
A triple kB promoter-luciferase reporter construct was a gift of Sankar
Ghosh (Yale University). HeLa cells were plated at a density of 23 105
in 12-well plates and were transfected with 100 ng kB-luciferase
plasmid plus Lipofectamine 2000 (Invitrogen) for 24 hr before the ad-
dition of 100 nM triptolide for 1 hr and 15 ng/ml recombinant (human)
TNF-a (Roche) for an additional 5 hr. The transfection efficiency of
HeLa cells was determined to be 80%–90%, and all samples were
normalized to protein concentration. Luciferase assays were per-
formed by using the Firefly luciferase kit as per manufacturer’s pro-
tocol (Promega), and results were obtained on the Wallac Victor2
1420 Multilabel Counter (Perkin Elmer).Acknowledgments
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